ArticleFrontiers in cardiovascular medicine2026
Jiangzhi ruanmai recipe alleviates atherosclerosis in ApoE
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerosis is a public health problem with high morbidity and mortality,Gut microbiota dysbiosis disrupts bile acid metabolism, impedes cholesterol excretion, promotes arterial lipid deposition, and accelerates atherosclerosis. Jiangzhi ruanmai recipe (JZRM) is a Chinese herbal medicine prescribed for the treatment of hyperlipidemia and atherosclerosis. However, the mechanism is unclear. Purpose: This study aims to investigate the effects and mechanisms of JZRM on Atherosclerosis. Methods: LC-MS analysis was first performed to characterize the chemical composition of JZRM. Next, an atherosclerosis model was established in ApoE Results: JZRM significantly reduced the lipid, glucose, and inflammation levels in mice; decreased the TBA levels of liver, intestine and faeces, and reduced the aortic plaque area; Second, JZRM increased the abundance and diversity of intestinal flora, significantly enhanced the level of intestinal bacteria that promote bile acid decomposition and excretion.Finally, JZRM significantly upregulated the protein expression of ABCA1, ABCG1, PPAR Conclusion: JZRM regulates gut microbiota-liver-cholesterol axis, promotes cholesterol synthesis and metabolism to alleviate atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.